Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care

Active Project Grant Awarded Last action

Award ID
R01CA261874
Recipient
Awarding agency
Obligated
$4,715,402

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date 83% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Survivors of childhood and adolescent cancer ("survivors") face high risks for early mortality and treatment- related late effects, including subsequent breast cancer. Approximately 30% of female survivors previously treated with chest radiation will develop breast cancer before age 50, a risk similar to BRCA1 mutation carriers. The children's oncology group recommends early screening for breast cancer (in those who received radiation) starting at age 25, but

Transactions

Action Obligated Date
Amendment $602,181
Amendment $705,394
Amendment $621,799
Amendment $12,880
Amendment $631,088
Amendment $631,088
Amendment $755,486
Original award $755,486

Subawards

Subrecipient Amount Awarded
Harvard Pilgrim Health Care, Inc. ThesubcontractPrincipal Investigator(PI),NatashaK.Stout, PhD, isanAssociateProfessor in… $62,123
Fred Hutchinson Cancer Center The Fred Hutchinson Cancer Center will:--Provide data from the CCSS study to Dr. Yeh for her project--Advise on related methodological and statistical issues… $45,248
ST Jude Children's Research Hospital Inc. Dr. Hudson is the Director Of the Cancer Survivorship Division and Co-Leader Of the Cancer Prevention & Control Program at St. Jude Children's Research… $18,715
Georgetown University JeanneMandelblatt, MD, ProfessorofMedicine, andJinaniJayasekera, PhD, Assistant Professor, atGeorgetownUniversitywillbesubcontractMultiplePrincipal… $51,988
University Of Wisconsin System The purpose of this research study is to leverage two NCI-funded Cancer Intervention and Surveillance Modeling Network (CISNET) models and data from the… $47,757
Albert Einstein College Of Medicine The subcontract Principal Investigator (PI), Clyde Schechter, MD, is a Professor at the Albert Einstein College of Medicine and a member of the CISNET Breast… $55,986
University Of Wisconsin System "The purpose of this research study is to leverage two NCI-funded Cancer Intervention and Surveillance Modeling Network (CISNET) models and data from the… $45,053
Harvard Pilgrim Health Care, Inc. "The subcontract Principal Investigator (PI), Natasha K. Stout, PhD, is an Associate Professor in the Department of Population Medicine at Harvard Medical… $70,424
Duke University Dr. Oeffinger is the Director of the Duke Center for Onco-Primary Care, the Director of the Duke Cancer Supportive Care and Survivorship Center, and Professor… $49,490

Quick answers

Who received award R01CA261874?

R01CA261874 was awarded to The Children's Hospital Corporation by National Cancer Institute (National Institutes of Health) on September 1, 2022.

How much is award R01CA261874 worth?

$4,715,402 has been obligated on R01CA261874.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login